Caen Cedex 5

• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended recruitment
  2024-513455-33-00 4 2014-09-11 Bone sarcoma
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended
  2024-515391-12-00 1 2025-03-15 Advanced Solid Tumors with AKT1 E17K Mutation
• A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab … Ended
  2024-513697-22-00 5 2024-11-07 non-small-cell lung cancer
• Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended
  2024-516299-13-00 4 2024-09-06 Resectable Gastric Cancer
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien … Ended
  2022-502584-38-00 5 2023-12-12 Locally advanced squamous cell carcinoma of the head and neck
• Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Ended
  2023-504153-12-00 4 2023-12-07 Advanced or Metastatic Solid Tumors
• Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C … Ended
  2023-503270-20-00 3 2023-11-29 recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me … Ended
  2022-502372-22-01 4 2023-10-19 Metastatic Breast Cancer HR+, HER2-
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 7 2023-06-02 Head and Neck Squamous Cell Cancer
• First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended
  2022-501183-17-00 7 2023-02-23 Non-Small Cell Lung Cancer
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) Ended
  2024-512826-26-00 4 2022-03-07 Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ b
• Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca … Ended
  2024-513707-14-00 5 2022-01-14 Only patients with oncologic locally advanced or metastatic tumour (lu
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma

Showing 241–264 of 283 trials